1. Home
  2. IZEA vs IFRX Comparison

IZEA vs IFRX Comparison

Compare IZEA & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IZEA Worldwide Inc.

IZEA

IZEA Worldwide Inc.

HOLD

Current Price

$4.91

Market Cap

69.1M

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.06

Market Cap

86.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IZEA
IFRX
Founded
2006
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.1M
86.0M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
IZEA
IFRX
Price
$4.91
$1.06
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
174.1K
7.7M
Earning Date
11-12-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$36,176,492.00
$73,729.00
Revenue This Year
N/A
N/A
Revenue Next Year
$15.91
$1,075.42
P/E Ratio
N/A
N/A
Revenue Growth
7.12
N/A
52 Week Low
$1.68
$0.71
52 Week High
$5.86
$2.82

Technical Indicators

Market Signals
Indicator
IZEA
IFRX
Relative Strength Index (RSI) 48.54 42.21
Support Level $4.78 $0.92
Resistance Level $5.15 $1.28
Average True Range (ATR) 0.28 0.11
MACD -0.03 -0.02
Stochastic Oscillator 18.11 30.42

Price Performance

Historical Comparison
IZEA
IFRX

About IZEA IZEA Worldwide Inc.

IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: